Literature DB >> 18710909

Improved antimicrobial activity of linezolid against vancomycin-intermediate Staphylococcus aureus.

Yukiko Watanabe, Hui-Min Neoh, Longzhu Cui, Keiichi Hiramatsu.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18710909      PMCID： PMC2573128          DOI： 10.1128/AAC.00676-08

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


× No keyword cloud information.
  10 in total

1.  An association between reduced susceptibility to daptomycin and reduced susceptibility to vancomycin in Staphylococcus aureus.

Authors:  Jean B Patel; Laura A Jevitt; Jeffery Hageman; L Clifford McDonald; Fred C Tenover
Journal:  Clin Infect Dis       Date:  2006-06-01       Impact factor: 9.079

2.  Evolution and resistance expression of MRSA. Evaluation of beta-lactam antibiotics against a set of isogenic strains with different types of phenotypic expression.

Authors:  K Asada; Y Inaba; E Tateda-Suzuki; K Kuwahara-Arai; T Ito; K Hiramatsu
Journal:  Acta Biochim Pol       Date:  1995       Impact factor: 2.149

3.  Dissemination in Japanese hospitals of strains of Staphylococcus aureus heterogeneously resistant to vancomycin.

Authors:  K Hiramatsu; N Aritaka; H Hanaki; S Kawasaki; Y Hosoda; S Hori; Y Fukuchi; I Kobayashi
Journal:  Lancet       Date:  1997-12-06       Impact factor: 79.321

Review 4.  Epidemiology and clinical impact of glycopeptide resistance in Staphylococcus aureus.

Authors:  C Ruef
Journal:  Infection       Date:  2004-12       Impact factor: 3.553

5.  Whole genome sequencing of meticillin-resistant Staphylococcus aureus.

Authors:  M Kuroda; T Ohta; I Uchiyama; T Baba; H Yuzawa; I Kobayashi; L Cui; A Oguchi; K Aoki; Y Nagai; J Lian; T Ito; M Kanamori; H Matsumaru; A Maruyama; H Murakami; A Hosoyama; Y Mizutani-Ui; N K Takahashi; T Sawano; R Inoue; C Kaito; K Sekimizu; H Hirakawa; S Kuhara; S Goto; J Yabuzaki; M Kanehisa; A Yamashita; K Oshima; K Furuya; C Yoshino; T Shiba; M Hattori; N Ogasawara; H Hayashi; K Hiramatsu
Journal:  Lancet       Date:  2001-04-21       Impact factor: 79.321

Review 6.  Oxazolidinone antibiotics.

Authors:  D J Diekema; R N Jones
Journal:  Lancet       Date:  2001-12-08       Impact factor: 79.321

7.  Induction of daptomycin heterogeneous susceptibility in Staphylococcus aureus by exposure to vancomycin.

Authors:  George Sakoulas; Jeff Alder; Claudie Thauvin-Eliopoulos; Robert C Moellering; George M Eliopoulos
Journal:  Antimicrob Agents Chemother       Date:  2006-04       Impact factor: 5.191

8.  Correlation between Reduced Daptomycin Susceptibility and Vancomycin Resistance in Vancomycin-Intermediate Staphylococcus aureus.

Authors:  Longzhu Cui; Eiji Tominaga; Hui-Min Neoh; Keiichi Hiramatsu
Journal:  Antimicrob Agents Chemother       Date:  2006-03       Impact factor: 5.191

9.  Cell wall thickening is a common feature of vancomycin resistance in Staphylococcus aureus.

Authors:  Longzhu Cui; Xiaoxue Ma; Katsuhiro Sato; Keiko Okuma; Fred C Tenover; Elsa M Mamizuka; Curtis G Gemmell; Mi-Na Kim; Marie-Cecile Ploy; N El-Solh; Vivian Ferraz; Keiichi Hiramatsu
Journal:  J Clin Microbiol       Date:  2003-01       Impact factor: 5.948

10.  Linezolid vs vancomycin: analysis of two double-blind studies of patients with methicillin-resistant Staphylococcus aureus nosocomial pneumonia.

Authors:  Richard G Wunderink; Jordi Rello; Sue K Cammarata; Rodney V Croos-Dabrera; Marin H Kollef
Journal:  Chest       Date:  2003-11       Impact factor: 9.410
  10 in total
  6 in total

1.  Clinical and microbiologic analysis of the risk factors for mortality in patients with heterogeneous vancomycin-intermediate Staphylococcus aureus bacteremia.

Authors:  Yong Pil Chong; Ki-Ho Park; Eun Sil Kim; Mi-Na Kim; Sung-Han Kim; Sang-Oh Lee; Sang-Ho Choi; Jin-Yong Jeong; Jun Hee Woo; Yang Soo Kim
Journal:  Antimicrob Agents Chemother       Date:  2015-04-06       Impact factor: 5.191

2.  Mutation of RNA polymerase beta subunit (rpoB) promotes hVISA-to-VISA phenotypic conversion of strain Mu3.

Authors:  Miki Matsuo; Tomomi Hishinuma; Yuki Katayama; Longzhu Cui; Maria Kapi; Keiichi Hiramatsu
Journal:  Antimicrob Agents Chemother       Date:  2011-07-11       Impact factor: 5.191

3.  walK and clpP mutations confer reduced vancomycin susceptibility in Staphylococcus aureus.

Authors:  Mitsutaka Shoji; Longzhu Cui; Risa Iizuka; Akira Komoto; Hui-min Neoh; Yukiko Watanabe; Tomomi Hishinuma; Keiichi Hiramatsu
Journal:  Antimicrob Agents Chemother       Date:  2011-05-31       Impact factor: 5.191

4.  Characterisation of a Staphylococcus aureus strain with progressive loss of susceptibility to vancomycin and daptomycin during therapy.

Authors:  Fred C Tenover; Scott W Sinner; Robert E Segal; Vanthida Huang; Shandline S Alexandre; John E McGowan; Melvin P Weinstein
Journal:  Int J Antimicrob Agents       Date:  2009-02-23       Impact factor: 5.283

5.  Correlation between vancomycin MIC values and those of other agents against gram-positive bacteria among patients with bloodstream infections caused by methicillin-resistant Staphylococcus aureus.

Authors:  N Patel; P Lubanski; S Ferro; M Bonafede; S Harrington; A Evans; K Stellrecht; T P Lodise
Journal:  Antimicrob Agents Chemother       Date:  2009-10-05       Impact factor: 5.191

6.  Prevalence of Slow-Growth Vancomycin Nonsusceptibility in Methicillin-Resistant Staphylococcus aureus.

Authors:  Yuki Katayama; Takuya Azechi; Motoyasu Miyazaki; Tohru Takata; Miwa Sekine; Hidehito Matsui; Hideaki Hanaki; Koji Yahara; Hiroshi Sasano; Kota Asakura; Tomoiku Takaku; Tomonori Ochiai; Norio Komatsu; Henry F Chambers
Journal:  Antimicrob Agents Chemother       Date:  2017-10-24       Impact factor: 5.191
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.